95 related articles for article (PubMed ID: 12400570)
21. Studies of various administration methods for lansoprazole injection using 24-hour intragastric pH monitoring.
Inoue M; Nakamura M
J Clin Gastroenterol; 1995; 20 Suppl 2():S17-21. PubMed ID: 7594332
[TBL] [Abstract][Full Text] [Related]
22. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
23. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers.
Verdú EF; Fraser R; Armstrong D; Blum AL
Scand J Gastroenterol; 1994 Dec; 29(12):1065-9. PubMed ID: 7886393
[TBL] [Abstract][Full Text] [Related]
24. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Ogawa N
Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
[TBL] [Abstract][Full Text] [Related]
25. Determining the optimal dose of lansoprazole injection by 24-hour intragastric pH monitoring.
Sugiyama M; Aoki T; Matsuo Y
J Clin Gastroenterol; 1995; 20 Suppl 2():S14-6. PubMed ID: 7594331
[TBL] [Abstract][Full Text] [Related]
26. Lansoprazole-induced thrombocytopenia.
Zlabek JA; Anderson CG
Ann Pharmacother; 2002 May; 36(5):809-11. PubMed ID: 11978156
[TBL] [Abstract][Full Text] [Related]
27. [Dosaging of proton pumps inhibitors].
Brørs O
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2397-9. PubMed ID: 16998554
[No Abstract] [Full Text] [Related]
28. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
29. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions.
Rizzo N; Padoin C; Palombo S; Scherrmann JM; Girre C
Eur J Clin Pharmacol; 1996; 49(6):491-5. PubMed ID: 8706775
[TBL] [Abstract][Full Text] [Related]
30. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
31. Treating Helicobacter pylori.
Howden CW; Hunt RH
Arch Intern Med; 1998 Nov; 158(21):2396-8. PubMed ID: 9827792
[No Abstract] [Full Text] [Related]
32. Anaphylaxis to lansoprazole with tolerance to omeprazole.
Aksu K; Kurt E
Allergol Immunopathol (Madr); 2012; 40(6):393-4. PubMed ID: 22115571
[No Abstract] [Full Text] [Related]
33. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs.
Weaver AL; Gitlin N
Arch Intern Med; 2002 Oct; 162(19):2248-9. PubMed ID: 12390074
[No Abstract] [Full Text] [Related]
34. Simplified lansoprazole suspension--a liquid formulation of lansoprazole--effectively suppresses intragastric acidity when administered through a gastrostomy.
Sharma VK; Vasudeva R; Howden CW
Am J Gastroenterol; 1999 Jul; 94(7):1813-7. PubMed ID: 10406240
[TBL] [Abstract][Full Text] [Related]
35. Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients.
Shimoyama T; Munakata A; Mizuki I; Akagi T; Fukuda S; Ohkawa K; Yoshida Y; Aisawa T; Sakata Y; Fukushi M
J Clin Gastroenterol; 1995; 20 Suppl 2():S125-7. PubMed ID: 7594328
[TBL] [Abstract][Full Text] [Related]
36. [Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal].
Paul G; Ramdani A; Mignon M; Vallot T; Forestier S; Cadiot G; Ruszniewski P; Joubert-Collin M
Gastroenterol Clin Biol; 1994; 18(8-9):695-701. PubMed ID: 7875436
[TBL] [Abstract][Full Text] [Related]
37. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and absolute bioavailability of lansoprazole.
Gerloff J; Mignot A; Barth H; Heintze K
Eur J Clin Pharmacol; 1996; 50(4):293-7. PubMed ID: 8803522
[TBL] [Abstract][Full Text] [Related]
39. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
40. Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori.
Furuta T; Futami H; Arai H; Hanai H; Kaneko E
J Clin Gastroenterol; 1995; 20 Suppl 2():S107-11. PubMed ID: 7594323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
